Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Benefits of the Inherited NeuroMetabolic Diseases Network (InNerMeD) in biomarkers development (CROSBI ID 633318)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Delaš, Ivančica ; Scarpa, Maurizio ; Barić, Ivo Benefits of the Inherited NeuroMetabolic Diseases Network (InNerMeD) in biomarkers development // 11th Annual Biomarkers Congress Workbook / Roberts, Cerlin (ur.). Oxford: Oxford Global, 2016. str. P5-P5

Podaci o odgovornosti

Delaš, Ivančica ; Scarpa, Maurizio ; Barić, Ivo

engleski

Benefits of the Inherited NeuroMetabolic Diseases Network (InNerMeD) in biomarkers development

Introduction: Early pre-symptomatic or prenatal diagnosis and new-born screening of inherited neurometabolic diseases (INMD) are crucial for application of the appropriate therapy as early as possible, in order to minimize impairment of brain function. Searching for novel biomarkers applicable in diagnosis and monitoring of diseases is continuous process. Methods: In order to increase medical and general awareness on INMD and potential biomarkers development, Inhereted NeuroMetabolic Disease (InNerMeD) Information Network is used. Results: Inhereted NeuroMetabolic Disease (InNerMeD) Information Network (www.innermed.eu) is the first European Network on INMD funded by the Directorate-General for Health and Consumers within the Second Health Programme of the European Commission (Grant Agreement No. 201212121 - Collaborative Project). The main objectives of the Network are: i) acquisition of critical mass of knowledge encompassing multi-specialist competences, ii) a further boost to research and technological innovation ; iii) creation of repository containing standardized data spanning research, clinical features, available therapies and off-label application, biomarkers and genetic data ; iv) dissemination of knowledge among physicians, patients and general stakeholders to anticipate diagnosis and supply an adequate therapy. Conclusion: The expected benefit from the InNerMeD network is to increase validated knowledge on INMD and to expand activities with networks of excellence focused on genetic CNS diseases.

InNerMeD network; biomarkers; new-born screening; inherited metabolic diseases

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

P5-P5.

2016.

objavljeno

Podaci o matičnoj publikaciji

11th Annual Biomarkers Congress Workbook

Roberts, Cerlin

Oxford: Oxford Global

Podaci o skupu

11th Annual Biomarkers Congress

poster

25.02.2016-26.02.2016

Manchester, Ujedinjeno Kraljevstvo

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti